Please assess the completion status of the following clinical trial:

Trial Title: OptiVol® Care Pathway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject (or subject's legally authorized representative) is willing and able to sign and date written consent form and Authorization for Access to and Use of Health Information~* Subject is at least 18 years of age~* Subject is willing and able to comply with Clinical Investigation Plan~* Subject is willing and able to transmit data using Medtronic CareLink® Network~* Subject has market released right atrial (RA) (if applicable), right ventricular (RV), and left ventricular (LV) (if applicable) leads and one of the following generators implanted: Concerto® CRT-D - Model C154DWK, Virtuoso® DR ICD - Model D154AWG, Virtuoso® VR ICD - Model D154VWC, Consulta™ CRT-D - Model D224TRK, Secura™ DR ICD - Model D224DRG, Secura™ VR ICD - Model D224VRC, or any future market released Medtronic generator with wireless telemetry, Cardiac Compass with OptiVol Fluid Status Monitoring, and that is supported by the Medtronic CareLink Network~Exclusion Criteria:~* Subject is enrolled in a concurrent study with the exception of a study approved by the Medtronic Clinical Trial Leader prior to enrollment~* Subject has life expectancy of less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monthly Review Arm (Type: EXPERIMENTAL): Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
- Quarterly Review Arm (Type: ACTIVE_COMPARATOR): Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).